Suppr超能文献

良性开放性乳腺活检中发现放射状瘢痕或复杂硬化性病变后乳腺癌的长期随访和风险。

Long term follow-up and risk of breast cancer after a radial scar or complex sclerosing lesion has been identified in a benign open breast biopsy.

机构信息

Primrose Breast Care Centre, Derriford Hospital, Derriford Road, Plymouth, PL6 8DH, UK.

出版信息

Eur J Surg Oncol. 2011 Aug;37(8):709-13. doi: 10.1016/j.ejso.2011.04.011.

Abstract

AIMS

Radial scars (RS)/complex sclerosing lesions (CSL) are rare, benign breast lesions of unknown aetiology. Associations with breast cancer have been suggested particularly with larger lesions. This study aims to identify the risk of developing subsequent breast cancer after excision of a benign RS/CSL with respect to lesion size and compared to expected rates in the normal UK population.

METHODS

A prospective cohort analysis was performed on patients diagnosed with RS/CSL in benign, open breast biopsy specimens over a 20-year period. The rate of subsequent breast cancer development was compared to expected rates in the normal UK population. Subjects were divided into two groups according to lesion size and the rates of subsequent breast cancer compared.

RESULTS

149 women without proliferative breast disease were followed for an average of 68 months. Five women developed subsequent cancer, equating to a rate of 0.84% per year. This compares to 0.32% per year in the normal population (RR 2.6, 95% CI 0.86-6.0). There were two subsequent cancers in the RS group and three subsequent cancers in the CSL group, P = 0.64.

CONCLUSIONS

The study finds no evidence to suggest that lesions greater than 10 mm (CSL) have any greater risk of developing cancer after excision than those below 10 mm (RS). Women treated for RS/CSL do not need any additional follow-up beyond routine mammographic breast screening. Additional surveillance should only be performed if there is associated pathology indicating an increased risk of subsequent malignancy.

摘要

目的

放射状瘢痕(RS)/复杂硬化性病变(CSL)是一种病因不明的罕见良性乳腺病变。特别是对于较大病变,已经提出了与乳腺癌相关的建议。本研究旨在确定切除良性 RS/CSL 后发生后续乳腺癌的风险与病变大小的关系,并与英国正常人群的预期发生率进行比较。

方法

对 20 年来良性开放性乳腺活检标本中诊断为 RS/CSL 的患者进行前瞻性队列分析。将后续乳腺癌发展的发生率与英国正常人群的预期发生率进行比较。根据病变大小将受试者分为两组,并比较后续乳腺癌的发生率。

结果

149 例无增生性乳腺疾病的女性平均随访 68 个月。5 例发生后续癌症,每年发生率为 0.84%。这与正常人群的 0.32%/年(RR 2.6,95%CI 0.86-6.0)相比。RS 组有 2 例后续癌症,CSL 组有 3 例后续癌症,P = 0.64。

结论

本研究没有证据表明切除后大于 10mm(CSL)的病变比小于 10mm(RS)的病变发生癌症的风险更高。治疗 RS/CSL 的女性不需要进行常规乳腺 X 线筛查以外的额外随访。仅在存在提示后续恶性肿瘤风险增加的相关病理时才应进行额外监测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验